Poster Session A

Wednesday, January 16
4:30-7:00 p.m.

A01 Clinical detection of melanoma via endogenous fluorophore lifetime imaging. Peter Pelionisz. UCLA David Geffen School of Medicine, Los Angeles, CA.

A02, PR07 The role of keratinocyte desmoglein 1 in shaping the melanoma tumor niche. Hope Burks. Northwestern University, Feinberg School of Medicine, Chicago, IL.

A03, PR08 Identifying the molecular and environmental factors mediating transformation of melanocyte stem cells to melanoma. Andrew White. Cornell University, Ithaca, NY.

A04 Analysis of molecular and immune features that correlate with serum lactate dehydrogenase (LDH) levels in patients (pts) with metastatic melanoma. Fernando Cintra Lopes Carapeto. University of Texas MD Anderson Cancer Center, Houston, TX.

A05 Molecular, immunological, metabolic, and radiomic associations of oxidative phosphorylation (OXPHOS) in melanoma brain metastases (MBMs). Grant Fischer. The University of Texas MD Anderson Cancer Center, Houston, TX.

A06 Differential response to autophagy in primary versus melanoma cells. Isabelle Miousse. University of Arkansas for Medical Sciences, Little Rock, AR.

A07 Activating mutations in uveal melanoma convey sensitivity to g-alpha q inhibition. Tyler Hitchman. MSKCC, New York, NY.

A08 The effect of irradiation with curcumin as a possible form of amelanotic melanoma treatment. Stanislaw Kwiatkowskis. Wroclaw Medical University, Wroclaw, Poland.

A09 Characteristics of uveal melanoma patients with central nervous system metastases. Sapna Patel. MD Anderson Cancer Center, Houston, TX.

A10, PR09 Pharmacological targeting of Gq reveals new pathways in uveal melanoma. Michael Onken. Washington University School of Medicine, Saint Louis, MO.

A11 Prognostic model for disease specific survival in anorectal melanoma. Priyadharsini Nagarajan. UT MD Anderson Cancer Center, Houston, TX.

A12 Presence of circulating tumor cells is an adverse risk factor for early stage uveal melanoma. Kartik Anand. Houston Methodist Cancer Center, Houston, TX.
A13  Clinical characteristics of responders to Nivolumab plus ipilimumab (Nivo/Ipi) in metastatic uveal melanoma. Michael Shephard. UT MD Anderson Cancer Center, Houston, TX.

A14, PR13  PTPN11 plays oncogenic roles and is a therapeutic target for BRAF wild-type melanomas. Minjung Kim. University of South Florida, Tampa, FL.

A15  New treatment opportunities by in vivo and in vitro screening approaches in melanoma. Luisa Lanfrancone. European Institute of Oncology, Milan, Italy.

A16, PR14  Defining isoform-specific roles for AKTs in BRAFV600E-driven melanoma. Jaymes Farrell. Tufts University, Boston, MA.

A17  A versatile mouse-modeling platform for rapid in vivo melanoma studies. Florian Karreth. H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

A18  Ccn1 expression by fibroblasts is required for melanoma metastasis. Andrew Leask. University of Western Ontario, London, ON, Canada.

A19  Discovery and characterization of selective and non-selective inhibitors of ErbB4 signaling: Putative targeted melanoma therapeutics. Lauren Lucas. Auburn University, Auburn, AL.

A20  17-aminogeldanamycin inhibits cytoprotective UPR pathways and cooperates with inhibitors of the MAPK signaling cascade in apoptosis induction. Aleksandra Mielczarek-Lewandowska. Medical University of Lodz, Lodz, Poland.

A21  Identification of putative melanoma driver mutations in the ErbB4 receptor tyrosine kinase gene. David Riese. Auburn University, Auburn, AL.


A23  Effects of anti-CTLA-4 and anti-PD-1 on memory T-cell differentiation and resistance to tumor relapse. Stephen Mok. MD Anderson Cancer Center, Houston, TX.

A24, PR02  Melanoma evolves complete immunotherapy resistance through acquisition of a hypermetabolic phenotype. Arthur Liu. The University of Texas MD Anderson Cancer Center, Houston, TX.

A25, PR01  A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. Livnat Jerby-Arnon. The Broad Institute of MIT and Harvard, Cambridge, MA.

A26  Humanized mouse model: A model to understand mechanisms of immune non-responsiveness to immune checkpoint inhibitors in melanoma. Rajasekharan Somasundaram. The Wistar Institute, Philadelphia, PA.

A27  Engineering a 3D melanoma microenvironment and identifying novel therapeutic targets. Vasanth Siruvallur Murali. UT Southwestern Medical Center, Dallas, TX.
A28 Identification of NGLY1-mediated protein deglycosylation as a vulnerable point in melanoma. Yu-Chieh Wang. University of North Texas Health Science Center, Fort Worth, TX.


A30, PR03 Non-Genomic BAP1 Aberrancy Drives Highly Aggressive Cutaneous Melanoma Phenotype. Scott Woodman. University of Texas MD Anderson Cancer Center, Houston, TX.

A31 A novel melanoma derived cyclic decapetide dimer mediates restoration of contact inhibition of growth and reversal of the malignant phenotype. George Lipkin. NYU Langone School of Medicine, New York, NY.

PR06 The glutaminase inhibitor CB-839 potentiates anti-melanoma activity of standard-of-care targeted therapies and immunotherapies. Vashisht Yennu Nanda. UT M.D. Anderson Cancer Center, Houston, TX.
Poster Session B

Thursday, January 17
12:30-3:00 p.m.

B01 Genome-scale shRNA screen provides insight into the role of CUL3 in adaptive mechanisms of resistance to mutant BRAF inhibition. Eliot Zhu. University of Iowa, Iowa City, IA.

B02, PR18 Comparative screening of skin-derived NCSCs, melanocytes, and melanoma developmental programs reveals LPAR1 in MAPKi resistance. Vito Rebecca. Wistar Institute, Philadelphia, PA.

B03, PR05 Unique lipid metabolite profiling in BRAFV600E inhibitor drug-resistant melanoma and their potential as drug target. Meng-Ting Chang. Agricultural Biotechnology Research Center, Academia Sinica, Taipei, Taiwan.

B04, PR17 Sleeping Beauty mutagenesis reveals a Src-dependent DBL GEF family signaling mechanism driving MAPK inhibitor resistance in BRAF mutant melanoma. Christopher Stipp. University of Iowa, Iowa City, Iowa.

B05 Sox10 differentially regulates receptor tyrosine kinase expression in melanomas. Claudia Capparelli. Thomas Jefferson University, Philadelphia, PA.

B06 Loss of SPRY1 expression in BRAF-mutant cutaneous melanoma inhibits cell proliferation and improves response to targeted therapy. Elisabetta Fratta. Centro di Riferimento Oncologico, IRCCS-National Cancer Institute, Aviano (PN), Italy.


B08 Identification and characterization of Rho family GTPases as drivers of drug resistance in BRAFV600 mutant melanoma. Jacob Schillo. University of Iowa, Iowa City, IA.

B09 Nitric Oxide Stimulates PI3K-AKT Pathway Activation by S-Nitrosylation of PTEN in Human Melanoma Cells. Zhen Ding. Department of Melanoma Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX.

**B11**  Prognostic biomarkers in stage II-III melanoma.  Emanuelle Rizk. Columbia University Irving Medical Center, New York, NY.

**B13**  Intrinsic microsomal PGE2 synthase-1 associates with poor patient survival and T cell infiltration, and regulates immunosuppression in human and mouse melanoma models.  Sun-Hee Kim. The University of Texas MD Anderson Cancer Center, Houston, TX.

**B14, PR15**  CD74 regulated inflammatory pattern is associated with TIL growth and favorable response to adoptive immunotherapy.  Suhendan Ekmekcioglu. UT., MD Anderson Cancer Center, Houston, TX.

**B15, PR16**  Specific activation of the G Protein-Coupled Estrogen Receptor inhibits melanoma and other cancers and potentiates immune and targeted therapies.  Todd Ridky. Univ. of Pennsylvania, Philadelphia, PA.

**B16**  The immune profile of sentinel lymph nodes in melanoma.  Georgia Beasley. Duke University, Durham, NC.

**B17**  VEGF removal delays the onset of acquired resistance to target therapy and increase the efficacy of immune checkpoint inhibitors in BRAF mutated melanoma.  Valentina Comunanza. Department of Oncology – University of Turin; Candiollo Cancer Institute FPO-IRCCS, Candiollo, Torino, Italy.

**B18**  The expression of CD74-regulated inflammatory markers in Stage IV melanoma: Risk of CNS metastasis and patient survival.  Dai Ogata. UT MD Anderson Cancer Center, Houston, Texas.

**B19**  Suppression of CD8+ T cell functions by melanoma cell-derived exosomes captured from plasma of patients with melanoma.  Priyanka Sharma. University of Pittsburgh, Pittsburgh, PA.

**B20**  Monitoring of melanoma progression utilizing multi-platform biomarkers of blood cell-free DNA.  Dave Hoon. John Wayne Cancer Institute, Santa Monica, CA.

**B21**  Arylsulfatase B (ARSB) is reduced in melanoma metastases and decline in ARSB increases programmed death-ligand (PDL)1.  Joanne Tobacman. University of Illinois at Chicago and Jesse Brown VAMC, Chicago, IL.

**B23, PR11**  Understanding the role of myddosome dynamics in melanoma using live cell imaging.  Bridget Kreger. AstraZeneca, Waltham, MA.

**B24, PR12**  Regulation of the tumor suppressive miR-29 family by oncogenic MAPK signaling in melanoma.  Olga Vera. Moffitt Cancer Center, Tampa, FL.

**B25**  Demographic characteristics and peripheral blood clinical laboratory variables predict irAE occurrence in patients with advanced melanoma receiving anti-PD-1 monotherapy.  Xue Bai. MGH, Boston, MA.

**B26**  Combinational effect of sulforaphane (SFN) and epigenetic demethylation agent 5-aza-2'-deoxycytidine (DAC) on metastatic melanoma.  Tung-chin Chiang. University of Arkansas for Medical Sciences, Little Rock, AR.


B29  Systemic anti-melanoma immunity induced by oncolytic adenovirus Delta-24-RGDOX. Hong Jiang. MD Anderson Cancer Center, Houston, Texas.

B30  The histone demethylase PHF8 epigenetically regulates the TGFbeta pathway to promote melanoma metastasis. Rana Moubarak. NYU School of Medicine, New York, NY.

B31  Strategic investments by the Melanoma Research Alliance in research and career development accelerate progress in melanoma prevention, diagnostics and treatment. Kristen Mueller. Melanoma Research Alliance, Washington, DC.

B32  A novel combination therapy for metastatic melanoma potentiates a gap junction positive feedback mechanism. Shoshanna Zucker. D'Youville School of Pharmacy, Buffalo, NY.